Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Banyu to Assign 60% of Its MRs for Marketing of Januvia
September 7, 2009
- What Women Want
September 7, 2009
- Pfizer, Astellas to Copromote Caduet
September 7, 2009
- J-TEC Submits Application for JACC
September 7, 2009
- Everolimus Approved in EU: Novartis
August 31, 2009
- Japan, China, South Korea Start Working-Level Regulatory Consultations
August 31, 2009
- Korosho to Promote Sharing of Know-how to Promote Use of Generics
August 31, 2009
- Sampling Tests Show Problems with Only 2 of 876 Products
August 31, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 31, 2009
- Leading Generic Houses Post Strong Growth in Both Sales, Profits
August 31, 2009
- CSL Behring Sponsors HAE Study Meetings for Doctors
August 31, 2009
- Levemir Does Not Increase Cancer Risk: Novo Nordisk
August 31, 2009
- Korosho to Start Japanese Version of Sentinel Initiative
August 31, 2009
- BUSINESS NEWS IN BRIEF
August 31, 2009
- Korosho to Prepare GL for Clinical Assessment of Antidepressants
August 31, 2009
- Cravit Ranked No. 1 on Both HP and GP Markets: Rep Track Survey
August 31, 2009
- Full-Scale Flu Epidemic May Have Begun: Health Minister
August 31, 2009
- Makers' FY2009 1st Qtr Business Roundup -2-
August 31, 2009
- GSK Starts Adjusting Shipments of Relenza due to Rush of Orders
August 31, 2009
- Makers' FY2009 1st Qtr Business Roundup -1-
August 31, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…